LIMINAL BIOSCIENCES

Serial Number 79293798
Registration 6413686
700

Registration Progress

Application Filed
Apr 16, 2020
Under Examination
Approved for Publication
Apr 27, 2021
Published for Opposition
Apr 27, 2021
Registered
Jul 13, 2021

Trademark Image

LIMINAL BIOSCIENCES

Basic Information

Serial Number
79293798
Registration Number
6413686
Filing Date
April 16, 2020
Registration Date
July 13, 2021
Published for Opposition
April 27, 2021
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Jul 13, 2021
Registration
Registered
Classes
005 040 042 044
+1 more

Rights Holder

Liminal BioSciences Inc.

98
Address
231 Dundas St. E
Belleville ON K8N 1E2
CA

Ownership History

Liminal BioSciences Inc.

Original Applicant
99
CA

Liminal BioSciences Inc.

Owner at Publication
99
CA

Liminal BioSciences Inc.

Original Registrant
99
CA

Liminal BioSciences Inc.

New Owner After Registration #1
98
CA

Legal Representation

Attorney
Timothy H. Hiebert

USPTO Deadlines

Next Deadline
714 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2021-07-13)
Due Date
July 13, 2027
Grace Period Ends
January 13, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

25 events
Date Code Type Description Documents
Dec 27, 2024 ADCH M CHANGE OF NAME/ADDRESS REC'D FROM IB Loading...
Dec 5, 2021 FINO P FINAL DECISION TRANSACTION PROCESSED BY IB Loading...
Nov 12, 2021 FIMP P FINAL DISPOSITION PROCESSED Loading...
Nov 12, 2021 FICS P FINAL DISPOSITION NOTICE SENT TO IB Loading...
Oct 13, 2021 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Loading...
Jul 13, 2021 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Apr 27, 2021 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Apr 27, 2021 PUBO A PUBLISHED FOR OPPOSITION Loading...
Apr 25, 2021 GPNX P NOTIFICATION PROCESSED BY IB Loading...
Apr 7, 2021 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Loading...
Apr 7, 2021 OP2R P NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Loading...
Apr 7, 2021 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Mar 23, 2021 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Mar 22, 2021 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Mar 21, 2021 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Mar 21, 2021 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Nov 2, 2020 RFNT P REFUSAL PROCESSED BY IB Loading...
Oct 10, 2020 RFRR P REFUSAL PROCESSED BY MPU Loading...
Oct 10, 2020 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Loading...
Sep 22, 2020 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Sep 19, 2020 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Loading...
Sep 18, 2020 CNRT R NON-FINAL ACTION WRITTEN Loading...
Sep 18, 2020 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 18, 2020 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Sep 17, 2020 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB Loading...

Detailed Classifications

Class 005
Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of asthma; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for the treatment of brain diseases and disorders, namely, epilepsy, alzheimer's, cerebral palsy, parkinson's disease, multiple sclerosis; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; pharmaceutical preparations for the treatment of dandruff; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, alzheimer's disease, parkinson's disease, huntington's disease and multiple sclerosis; anti-viral agents; antibiotics; antivirals; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely, growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the spinal cord systems and related cartilage and tissue; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of erectile dysfunction; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of gastrointestinal disorders; pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hypercholesterolemia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely, diabetes, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of motion sickness; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of myalgia and neuralgia; pharmaceutical preparations for the treatment of neurological diseases, namely, alzheimer's, huntington's disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident, stroke, parkinson's disease, multiple sclerosis, myasthenia gravis
Class 040
Manufacture of pharmaceuticals to the order and specification of others
Class 042
Development of pharmaceutical preparations and medicines; pharmaceutical product evaluation; pharmaceutical research and development; pharmaceutical research services; research on the subject of pharmaceuticals
Class 044
Pharmaceutical advice; pharmaceutical consultancy services; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; providing information to patients in the field of administering medications; medical care services relating to patient treatment, excluding services in the field of psychology and mental health
Class 045
Providing personal support services for families of patients with life threatening disorders, namely, emotional counseling and emotional support, and coordinating the procurement and administration of medication; providing companionship services for families of patients with life threatening disorders

Classification

International Classes
005 040 042 044 045

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIOSCIENCES"